The latest GU-cancer news from reliable sources can be found on the MediPaper website. Get an instant update with the latest developments in GU-cancer.

Multimodal Approaches Emerging in Locally Advanced Prostate Cancer

Edouard J. Trabulsi, MD, discusses emerging multimodal treatment approaches for patients with locally advanced prostate cancer.

Read full article (External website)

Death due to cancer on the decline for most tumours in Europe

The exceptions are death due to lung and pancreatic carcinoma in women which are both still on the rise, according to a new study, published in Annals of Oncology on the 19th of March 2018.

Researchers predict that the death rates for most types of cancer will be lower in 2018 when compared to 2012 in the European Union.

The study, led by Carlo La Vecchia (MD) of the University of Milan, shows that death due to colorectal cancer (CRC) is on the decline in Europe. The researchers call the drop in death-rates of CRC, which is the most common cause of cancer-death in non-smoking males and females, one of the major achievements in the management of oncologic diseases over the recent years.

Key numbers for CRC:

  • CRC is the second highest cause of cancer-death: 177,400 (male: 98,000 in men; female 79,400);
  • Due to the ageing population, the absolute quantities of fatalities have risen since 2012;
  • In contrast, the age-standardised rates will decrease by 6.7% in men (15.8 per 100,000) and 7.5% in women (9.2 per 100,000).

Risk factors for CRC include:

  • Tobacco
  • Alcohol
  • Obesity
  • Diabetes
  • Sedentary lifestyle
  • Unhealthy diet

The use of oral contraceptives and hormone-replacement therapy in women may partly explain the decreased risk in females. Furthermore, the use of aspirin for prevention of cardiovascular disease and effective screening may further contribute to a decrease in the incidence of the disease in both sexes.

Key numbers for all cancers in Europe:

  • In 2018, 1.4 million cancer deaths are predicted, up from 1.3 million in 2012.
  • Death-rates have fallen by 10.3% in men and 5% in women
  • Age-standardised death rates in 2018 are predicted to be 130 per 100,000 for men and 84 per 100,000 for women.

Citations

  1. Malvezzi M et al. Ann Oncol. doi:10.1093/annonc/mdy033

Expert Discusses Potential Expansions to the Treatment Landscape in RCC

Treatment of renal cell carcinoma (RCC) is awaiting the potential integration of combinations of immuno-oncology agents like nivolumab (Opdivo) and ipilimumab (Yervoy), or combinations of targeted therapies with checkpoint inhibitors into the treatment paradigm. In an interview with Targeted Oncology, Robert A. Figlin, MD, discusses the expanding RCC armamentarium and balancing the benefits and risks of standard and emerging treatments to achieve optimal outcomes.

Read full article (External website)

Expert Discusses Bone-Targeting Agents in Prostate Cancer

Robert B. Den, MD, discusses bone-targeting agents in prostate cancer and the potential future of combinations.

Read full article (External website)

Enzalutamide Granted FDA

Based on data from the Phase 3 PROSPER trial, a supplemental new drug application for enzalutamide for the treatment of men with nonmetastatic castration-resistant prostate cancer has been granted a priority review by the FDA, according to Pfizer and Astellas, the companies developing the antiandrogen agent.

Read full article (External website)

Prostate Cancer Screening and Surveillance Continue to Evolve

William K. Kelly, DO, discusses the evolving imaging techniques and emerging therapeutic approaches in prostate cancer.

Read full article (External website)

Metastatic Prostate Cancer Project Explores a New Approach to Genomics Research

The project aims to improve understanding of prostate cancer genomics through direct-to-patient approach

Read full article (External website)

EMA Suggests Extension of Therapeutic Indications for Denosumab

Extension of indication includes the avoidance of skeletal-related events in grown-ups with late-stage malignancies involving the bone

On 22 February 2018, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending towards a change in the marketing authorisation for denosumab (licensee: Amgen Europe BV).

The following extension of the label was adopted by the CHMP:

  • Prevention of skeletal-related events in adults with advanced malignancies involving bone (e.g. pathological fracture, radiation to the bone, spinal cord compression, or surgery to the bone).

Previously, denosumab was only indicated for the prevention of skeletal-related events in adults with bone metastases from solid tumours.

Reference:
http://www.esmo.org/Oncology-Information/EMA-Endorses-Extension-of-Therapeutic-Indications-for-Denosumab2

Immune-Modified Response Criteria in Solid Tumours

Analyzis of atezolizumab data in clinical trials including NSCLC, mUC, RCC and melanoma patients may inform additional modifications to response evaluation criteria

Read full article (External website)

Enfortumab Vedotin Granted FDA

Enfortumab vedotin has been granted a breakthrough therapy designation by the FDA for the treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint therapy. These findings have been released by Seattle Genetics and Astellas, the manufacturers of the antibody-drug conjugate.

Read full article (External website)

Genetic Testing Helps Guide Treatment in Prostate Cancer

Genetic Testing Helps Guide Treatment in Prostate Cancer

2018-03-28 22:15:00

Veda Giri, MD, discusses the developing role of genetic testing for the screening and management and of patients with prostate cancer.

Source

EMA Recommends Extensions of Indications for Cabozantinib

2018-03-27 12:41:00

New indication concerns treatment-naive adults with intermediate or poor risk advanced RCC

Source